SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study

被引：0

作者：

Qin, Shuqui ^{[1
]}

Li, Jin ^{[2
]}

Zhou, Aiping ^{[3
]}

Zhang, Yanqiao ^{[4
]}

Yuan, Xianglin ^{[5
]}

Zhu, Liangjun ^{[6
]}

Qin, Baoli ^{[7
]}

Zeng, Shan ^{[8
]}

Shen, Lin ^{[9
]}

Yuan, Ying ^{[10
]}

Wang, Weibo ^{[11
]}

Liang, Jun ^{[12
]}

Zhang, Xianwen ^{[13
]}

Ye, Feng ^{[14
]}

Chen, Ping ^{[15
]}

Wang, Huaizhang ^{[16
]}

Yu, Zhenyan ^{[17
]}

Yue, Lu ^{[18
]}

Fang, Yong ^{[19
]}

Xiong, Jianping ^{[20
]}

Yang, Jianwei ^{[21
]}

Wan, Yiye ^{[22
]}

Yin, Xianli ^{[23
]}

Wang, Wenling ^{[24
]}

Xu, Nong ^{[25
]}

Wang, Xiaohong ^{[26
]}

Xiao, Zemin ^{[27
]}

Su, Huafang ^{[28
]}

Wang, Ying ^{[29
]}

Gu, Kangsheng ^{[30
]}

Tu, Shuiping ^{[31
]}

Wang, Zishu ^{[32
]}

Liu, Bo ^{[33
]}

Hu, Xiaohua ^{[34
]}

Liu, Weixian ^{[35
]}

Li, Xiaofeng ^{[36
]}

机构：

[1] Nanjing Jiangning Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China

[2] Shanghai East Hosp, Dept Med Oncol, 1,800 Yuntai Rd, Shanghai 200123, Peoples R China

[3] Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, Beijing, Peoples R China

[4] Harbin Med Univ, Canc Hosp, Dept Pathol, Harbin, Heilongjiang, Peoples R China

[5] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Med Oncol, R China, Wuhan, Hubei, Peoples R China

[6] Jiangsu Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China

[7] Liaoning Canc Hosp & Inst, Dept Gastroenterol, Shenyang, Liaoning, Peoples R China

[8] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China

[9] Beijing Canc Hosp, Dept Med Oncol, Beijing, Peoples R China

[10] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[11] Shandong Prov Hosp, Dept Chemotherapy, Jinan, Peoples R China

[12] Peking Univ, Int Hosp, Dept Med Oncol, Beijing, Peoples R China

[13] Northern Jiangsu Peoples Hosp, Dept Med Oncol, Yangzhou, Jiangsu, Peoples R China

[14] Xiamen Univ, Affiliated Hosp 1, Dept Med Oncol, Xiamen, Fujian, Peoples R China

[15] Ningxia Med Univ, Gen Hosp, Dept Med Oncol, Yinchuan, Ningxia, Peoples R China

[16] Henan Canc Hosp, Dept Integrated Chinese & Western Med, Zhengzhou, Henan, Peoples R China

[17] Mudanjiang Tumor Hosp, Dept Med Oncol, Mudanjiang, Heilongjiang, Peoples R China

[18] Qingdao Municipal Hosp Grp, Dept Oncol, Qingdao, Shandong, Peoples R China

[19] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[20] Nanchang Univ, Affiliated Hosp 1, Dept Med Oncol, Nanchang, Jiangxi, Peoples R China

[21] Fujian Canc Hosp, Dept Abdominal Oncol, Fuzhou, Fujian, Peoples R China

[22] Jiangxi Canc Hosp, Dept Gastroenterol, Nanchang, Jiangxi, Peoples R China

[23] Cent South Univ, Canc Hosp, Xiangya Sch Med, Dept Gastroenterol & Urol, Changsha, Hunan, Peoples R China

[24] Guizhou Med Univ, Dept Abdominal Oncol, Affiliated Hosp, Guiyang, Guizhou, Peoples R China

[25] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[26] Zhejiang Canc Hosp, Dept Abdominal Oncol, Hangzhou, Zhejiang, Peoples R China

[27] First Peoples Hosp Changde City, Dept Oncol, Changde, Hunan, Peoples R China

[28] Wenzhou Med Univ, Affiliated Hosp 1, Dept Radiotherapy, Wenzhou, Zhejiang, Peoples R China

[29] China Med Univ, Shengjing Hosp, Dept Med Oncol, Shenyang, Liaoning, Peoples R China

[30] Anhui Med Univ, Affiliated Hosp 1, Dept Med Oncol, Hefei, Anhui, Peoples R China

[31] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Med Oncol, Shanghai, Peoples R China

[32] First Affiliated Hosp, Bengbu Med Coll, Dept Med Oncol, Bengbu, Anhui, Peoples R China

[33] Shandong Canc Hosp & Inst, Dept Gastroenterol, Jinan, Shandong, Peoples R China

[34] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, Nanning, Guangxi, Peoples R China

[35] Binzhou Peoples Hosp, Dept Med Oncol, Binzhou, Shandong, Peoples R China

[36] Quanzhou First Hosp, Dept Med Oncol, Quanzhou, Fujian, Peoples R China

来源：

CANCER COMMUNICATIONS | 2024年 / 44卷 / 08期

关键词：

D O I：

10.1002/cac2.12586

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：910 / 914

页数：5

共 50 条

[1] Irinotecan plus raltitrexed as second-line chemotherapy for metastatic colorectal cancer: A retrospective study
Lian, Jie
Wang, Ren
Wang, Xin
Pang, Xiangyi
Xu, Benjie
Tang, Shuli
Shao, Jiayue
Lu, Haibo
ONCOLOGY LETTERS, 2024, 28 (03)
[2] Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer
Vyzula, R
Kocáková, I
Demlová, R
Kiss, I
Dusek, L
Jarkovsky, J
NEOPLASMA, 2006, 53 (02) : 119 - 127
[3] A pilot study of Irinotecan plus raltitrexed as second-line treatment for advanced colorectal cancer.
Qu, Xiujuan
Wu, Zhenhai
Wang, Shuo
Qu, Jinglei
Zhang, Lingyun
Liu, Jing
Shi, Jing
Zhang, Jingdong
Liu, Yunpeng
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial
Li, Sheng
Li, Xiaoyou
Zhu, Qianni
Gao, Jin
Zhu, Chunrong
Zhu, Liangjun
CANCER CONTROL, 2024, 31
[5] Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
Cheng, Ke
Zhou, Yu-Wen
Chen, Ye
Li, Zhi-Ping
Qiu, Meng
Liu, Ji-Yan
CANCER CONTROL, 2022, 29
[6] Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
Cheng, Ke
Zhou, Yu-Wen
Chen, Ye
Li, Zhi-Ping
Qiu, Meng
Liu, Ji-Yan
CANCER CONTROL, 2022, 29
[7] Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
Cheng, Ke
Zhou, Yu-Wen
Chen, Ye
Li, Zhi-Ping
Qiu, Meng
Liu, Ji-Yan
CANCER CONTROL, 2022, 29
[8] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
Deng, Ting
Zhang, Le
Liu, Xiao-jian
Xu, Jian-ming
Bai, Yu-xian
Wang, Yan
Han, Yu
Li, Yu-hong
Ba, Yi
MEDICAL ONCOLOGY, 2013, 30 (04)
[9] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
Ting Deng
Le Zhang
Xiao-jian Liu
Jian-ming Xu
Yu-xian Bai
Yan Wang
Yu Han
Yu-hong Li
Yi Ba
Medical Oncology, 2013, 30
[10] The efficacy and safety of irinotecan plus raltitrexed as second-line treatment in advanced colorectal cancer (ACC) patients: A summary analysis of a multicenter, phase II trial
Qu, X.
Liu, Y.
Teng, Z.
Zhang, Y.
Zheng, D. Z.
Man, L.
Wang, Z.
Wang, Y.
Zhang, J.
Zhang, H.
Liu, J.
Chen, H.
Xiao, W. J.
Jiang, Y.
Zhang, J.
Liu, S.
Wang, C.
ANNALS OF ONCOLOGY, 2021, 32 : S546 - S546

← 1 2 3 4 5 →